|  |  |
| --- | --- |
| **Title** | Ongoing REB Review Activities |
| **SOP Code** | REB-SOP 404-002 |
| **N2/CAREB SOP CODE** | SOP-404-003 |
| **Effective Date** | YYYY-MM-DD |

|  |  |  |
| --- | --- | --- |
| **Status** | **Name and Title** | **Date** |
| ***Author of Harmonized Template*** | REB SOPs developed by CATALIS Network | 2023-05-01 |
| ***Approved*** | REB Full Board Meeting XXX | YYYY-MM-DD |
| ***[Approved] or [Acknowledge receipt]*** | CA XXX | YYYY-MM-DD |

**Table of Content**

1 Purpose 1

2 Scope 1

3 Responsibilities 2

4 Definitions 2

5 Procedures 2

5.1 Amendments to Approved Research 3

5.2 Reportable Events 4

5.3 Other reports 7

5.4 Time frames for reporting events to the REB 7

5.5 Review of Reportable Events by the REB 8

6 References 11

7 Revision History 11

8 Appendices 11

1. Purpose

This SOP describes the procedures for the ongoing review activities that occur after the initial Research Ethics Board (REB) approval of a research project and prior to the next formally scheduled continuing annual review of the research project.

1. Scope

This SOP pertains to REBs that review human participant research in compliance with applicable regulations and guidelines.

1. Responsibilities

All REB members, designated REB office personnel and Researchers are responsible for ensuring that the requirements of this SOP are met.

The Researcher is responsible for reporting to the REB any new information generated throughout the course of the research that might affect the rights, safety and well-being of research participants, including reportable events that meet the reporting criteria as per this SOP.

The Researcher is responsible for reporting to the REB any information about the conduct of the research that could affect the rights, safety and well-being of research participants, including information about any serious or continuing non-compliance.

When action is taken by the REB to ensure the protection of the rights, safety, and well-being of participants (e.g., for an unanticipated problem involving risks to participants or others) the REB is responsible for communicating the decision to the Researcher and, at the discretion of the board, relevant Organizational Official(s). The REB has the authority to notify the sponsor and/or the appropriate regulatory authorities of any event or exceptional circumstances that meet reporting criteria. The REB may delegate regulatory authority reporting (as applicable) to the organization.

The REB Chair or designee is responsible for reviewing all reportable events submitted to the REB as well as any proposed amendment to the research, and for determining the type of review (i.e., delegated or Full Board) or action required. The REB must find that the criteria for approval are met before providing approval.

The REB members are responsible for reviewing any new information, reportable event or proposed amendment that are assigned to them or that are assigned to a Full Board meeting, and for recommending the appropriate course of action.

1. Definitions

See glossary of terms.

1. Procedures

In addition to the formally scheduled continuing annual review, the REB must receive and review any new information generated throughout the course of the research that might affect the rights, safety and well-being of research participants and/or for which a preventative or corrective action is possible.

Such information may include: amendments, reportable events, relevant reports, or any other new information that may affect the safety and well-being of the research participants or the conduct of the research.

Modifications to the approved research may not be initiated without prior REB review and approval except where necessary to eliminate apparent immediate hazards to human participants. If changes are made to eliminate immediate hazards, the Researcher must notify the REB immediately.

**Multi-centered Research in Québec[[1]](#footnote-1)**

* The REB will apply this SOP to studies for which it acts as the Evaluating REB for multi-centered research within the Québec health care network.
* In a multi-center study conducted by a different researcher at participating institutions with the same sponsor, each investigator is responsible for submissions of reportable events to the evaluating REB. The local researcher must submit in accordance with this SOP.
* Should researchers consider that the reportable event requires institutional involvement to ensure local participant safety and well-being, they may choose to inform the “personne formellement mandatée”.
* An investigator within the Québec health care network who submits an amendment for approval to the Evaluating REB, must forward the approved amended documents as well as a copy of the original document with approved changes highlighted to the mandated person in each public institution where the research is taking place.
* For multi-centre trials within the Québec health care network, all participating sites within the Québec health care network covered by the evaluating REB’s approval will be considered local.
* Requests to convert a study into a multicentre project or to add at least one site to a multi-centre study must be done via the Nagano platform, using the appropriate Form.
  1. Amendments to Approved Research
     1. The Researcher is responsible for submitting to the REB any change to an approved project. Changes to the approved study may include, for instance, modifications to the research protocol, to the consent form, to the Investigator Brochure (IB) or product monograph (PM), to the participant materials (e.g., wallet cards, diary cards, recruitment materials), to who the Researcher is, etc.;
     2. When the amendment is the result of a sponsor safety notice or action letter, this document must be appended to the amendment request;
     3. When the amendment includes a change to the consent form, the Researcher must indicate his/her recommendation as to whether the new information should be provided to current and/or past research participants;[[2]](#footnote-2)
     4. The REB Chair or designee pre-reviews the amendment to determine the appropriate level of REB review required (i.e., Full Board or delegated review) in accordance with REB SOP Delegated Review. If the proposed change represents more than minimal risk, it must be reviewed by the REB at a Full Board meeting. Amendments that may be classified as more than minimal risk may include:

Addition of genetic testing, new genetic tests, or tissue banking where genetic testing may or will be performed,

Addition of an open label extension phase following a randomized trial,

Emergency amendments that arise because of participant safety, which may include, but are not limited to:

A change in the recruitment that may affect confidentiality or the perception of coercion,

A change in experimental procedure or research population.

* + 1. For amendments requiring Full Board review, the designated REB office personnel assigns the amendment to the next available Full Board meeting. For amendments that meet the criteria for delegated review, the designated REB office personnel will assign the amendment to the designated reviewer(s);
    2. When an amendment involves revisions to the consent form, the REB will consider the recommendations of the Researcher in determining if, how and when the new information should be provided to the research participants and whether re-consent is required;
    3. Amendments may not be implemented prior to the REB review and approval, except when necessary to eliminate immediate hazards to participants. A change to the research that was initiated without prior REB review to eliminate an apparent immediate hazard to a research participant must be reported to the REB immediately;
    4. Amendments considered to be administrative in nature (for example, change of address or change in administrative research staff) that have no impact on participants or their well-being may be submitted at the time of formally scheduled continuing annual review of the project;
    5. The REB must find that the criteria for approval are still met in order to approve the amendment. Some documents submitted in an amendment may be acknowledged.
  1. Reportable Events

The Researcher is responsible for submitting reportable events or findings that meet the REB’s reporting criteria in accordance with this SOP and within the time frame specified in section 5.4. All reports submitted to the REB must have all research participant identifiers removed (i.e., participant research number only); The Researcher must determine if an event meets the REB reporting criteria:

As a general rule, any new information that would require a modification to the Investigator’s Brochure, the research or the consent form, or would prompt an action by the REB to ensure protection of research participants; any unanticipated problem, event or report that could significantly impact the overall conduct of the research or alter the participants’ willingness to participate or the REB’s approval or favorable opinion to continue the research, must be reported to the REB.

The Researcher must report the following to the REB, via NAGANO, within the time frame specified by the REB (5.4).

* + 1. Local Serious Adverse Events (SAE):

The Researcher must report to the REB any local serious adverse event that, in the opinion of the Researcher, meets all of the following criteria:

1. Unexpected;
2. Related or possibly related to participation in the research; and
3. Suggests that the research places research participants or others at a greater risk of harm than previously identified at time of review and approval.

The report submitted to the REB, via Nagano, must include all of the following information:

1. The description of the adverse event;
2. Previous safety reports concerning similar events, if available;
3. An analysis of the significance of the current adverse event; and
4. If applicable, the proposed modifications to the conduct of the research project and/or to the informed consent form and/or a list of corrective actions to be taken in response to the event;
5. A copy of the sponsor’s report, if available.

Any applicable form completed/required by the sponsor, if any, (e.g., SAE form), must be uploaded to Nagano;

Once a local SAE is reported to the REB, subsequent important follow-up reports related to the SAE should be submitted as soon as available. The follow-up reports from the sponsor must be transmitted when updating the reportable event. All initial and subsequent follow-up reports will be retained with the initial declaration.

* + 1. Non-Local (External) Serious Adverse Events (SAE)

The Researcher must report to the REB, any non-local serious adverse event that, in the opinion of the Researcher, meets all of the following criteria:

1. Unexpected;
2. Related or possibly related to participation in the research;
3. Suggests that the research places research participants or others at a greater risk of harm than previously identified at time of review and approval;

**AND**

1. Requires a change to the research and/or informed consent form and/or requires immediate notification to participants for safety reasons.

The report submitted to the REB, via Nagano, must include all of the information listed in section 5.2.1.

* + 1. Deviations to Previously Approved Research

The Researcher must report to the REB, in Nagano, any local deviation that meets the following reporting criteria:

* Deviations that, in the opinion of the Researcher: jeopardize the safety of research participants, the research efficacy, data integrity, or that could otherwise impact participant rights, safety or well-being;
* Any sponsor-approved waiver to the participant eligibility criteria;
* Any change in the approved process for obtaining consent (e.g., improper translation, current consent form not implemented);
* Any deviation that leads to an SAE.
  + 1. Privacy Breaches

The Researcher must report to the REB, in Nagano, any unauthorized collection, use, or disclosure of personal information including, but not limited to:

* The collection, use and disclosure of personal information that is not in compliance with the applicable legislation or regulation,
* Circumstances where personal information is stolen, lost or subject to unauthorized use or disclosure or where records of personal information are subjected to unauthorized copying, modifications or disposal,
* Any unauthorized collection, use or disclosure of personal information done in the context of the research project but that was not approved by the REB.

The breach must be reported to the REB and, as applicable, to the appropriate Organizational Official(s) as soon as the Researcher becomes aware of the breach.

* + 1. Research Participant Complaint

The Researcher must report to the REB, in Nagano, any concern raised by a participant about their rights as a research participant or about ethical issues related to the research as per REB-SOP 406-002.

* + 1. Other Reportable Events and Information

The Researcher is responsible for reporting to the REB, using the appropriate Nagano forms, circumstances such as:

* Any change to the risks or potential benefits of the research, including:
* An interim analysis indicating that participants have a rate of response to treatment different than expected,
* Safety monitoring indicating that a particular side effect is more severe or more frequent than expected,
* Information published from another research project that shows that an arm of the research is of no therapeutic value;
* A change in Health Canada or FDA safety labeling, approval status or withdrawal from market of a drug, device, health product, genetic therapy or biologic used in the project;
* Any unanticipated problem or other event that could significantly impact the conduct of the research at the site (e.g., concerns of non-compliance, institutional feasibility issues etc.);
* Findings of an inspection or audit relevant to the safety and well-being of the participants: The Researcher must report to the REB a summary of any relevant audit or inspection finding relevant to the safety and well-being of the participants following a Health Canada inspection, an FDA or other regulatory audit, an internal Quality Assurance audit, or other audits at the site.
  1. Other reports

The Researcher is responsible for submitting to the REB, using Nagano, reports related to the research in accordance with 5.4:

If the sponsor requires the submission to the REB of reports that are generated in accordance with the research protocol or that are routine or random **and that do not require action** to protect the safety and well-being of research participants, these reports may be submitted at the time of formally scheduled continuing annual review. The REB will acknowledge receipt of such reports.

* 1. Time frames for reporting events to the REB

The REB must be notified of reportable events as described in this SOP in accordance with the following timelines:

|  |  |  |
| --- | --- | --- |
| **REB notification of…** | **Time delay (calendar days)** | **Follow up required** |
| * + 1. Amendments | | |
| 1. Undertaken immediately to protect participants | Immediately | REB review and approval of amendments |
| 1. All other amendments | Report prior to introducing any change | REB review and approval are required prior to implementation of the amendments |
| * + 1. All reportable events as described herein | | |
| 1. Reportable events in context of death and/or life-threatening reactions | Within 7 days of researcher becoming aware of the event | A detailed report containing an analysis of the event, its consequences and corrective measures taken must be submitted within 8 days of the first report |
| 1. All other reportable events | Within 15 days of researcher becoming aware of the event |  |
| 1. Any new information that may adversely affect the safety of the research participants or the conduct of the research | Within 15 days of researcher becoming aware of this info |  |
| * + 1. Other reports | | |
| Scheduled, routine or random reports without identified impact on participant safety or well-being or required changes | Submit at the time of continuing review if required by the Sponsor. | REB acknowledgement letter will be sent. |

* 1. Review of Reportable Events by the REB
     1. The designated REB office personnel will screen the submission for completeness and to ensure that the reportable event form was attached, if applicable;
     2. The designated REB office personnel may route the submission back to the Researcher to request clarifications, missing documents or additional information;
     3. The designated REB office personnel will assign the submission to REB reviewer(s);
     4. The assigned REB reviewer(s) will conduct a review of the report and determine if any action or follow-up is required. The assigned reviewer(s) may request further information from the Researcher;
     5. When reviewing a reportable event, the REB must:

Assess the appropriateness of any corrective or preventative measure proposed by the sponsor and/or Researcher,

Consider any additional appropriate measure that may or may not have been identified or proposed by the sponsor and/or Researcher,

Consider whether the project still satisfies the requirements for REB approval, in particular whether risks to research participants are still minimized and reasonable in relation to the anticipated benefits (if any) to the research participants, and whether the knowledge that may reasonably be expected to accrue from the project is sufficiently important,

Consider whether some or all of the research participants should be notified of the events (i.e., if it may affect participants’ willingness to continue participating in the research), and

Consider whether suspension or termination of the ethics approval of the research is warranted;

* + 1. Privacy breaches are reviewed by the REB Chair or designee, and any recommendation including remedial action is determined in consultation with the organization’s responsible authority;
    2. If the event does not raise concerns and does not appear to involve risks to research participants or others, the REB Chair or designee acknowledges the report, and no further action is required;
    3. If the REB Chair or designee determines that immediate action is required to protect the safety and well-being of research participants, he/she may:

Put recruitment of new participants on hold, including participants in the screening process,

Suspend ethics approval of the research (put study on Hold),

Take any other action deemed necessary;

* + 1. If the event raises concerns or involves risk to research participants such that REB action is required, the item must subsequently be reviewed at a Full Board meeting;
    2. For reportable events reviewed at a Full Board meeting, the REB determines whether further action is required. Possible actions that could be taken by the REB include, but are not limited to:

Placing a hold on the research pending receipt of further information from the Researcher,

Requesting modifications to the research,

Requesting modifications to the consent form,

Requesting additional information be provided to past participants,

Requesting current participants be notified when such information might affect the participants willingness to continue to take part in the research, and requiring that current participants re-consent for ongoing participation,

Altering the frequency of continuing review,

Observing the research or the consent process,

Requiring additional training of the Researcher and research staff,

Terminating or suspending the research,

If the REB determines that the event does not raise concerns about risks to research participants, the REB may decide that no further action needs to be taken;

* + 1. Amendments to consent:
       1. Information relevant to consent that becomes available during a research project or after it has been completed/terminated:

The REB reviews and approves the information that must be brought to the attention of participants of an ongoing project, the process to disclose to participants potential long-term health effects during or after research participation, and changes to the consent form that require that new information be transmitted to participants;[[3]](#footnote-3)

* + - 1. The Researcher informs participants of any new information that may affect their willingness to continue to participate in research (e.g., significant change in the project or its associated risks),[[4]](#footnote-4) as well as of any new information regarding the potential impacts of the research project on their long-term health, even if their participation has already ended;
      2. The REB determines:

1. The nature of the new information to be transmitted to participants whose participation is ongoing, and the documentation that is required,
2. Whether an update to the consent form is required,
3. The process that must be put in place to allow participants to reconsent to participating in the ongoing research project;[[5]](#footnote-5)
   * + 1. If applicable, the REB may allow consent to be obtained orally via a telephone conversation during which the updated information would be provided.[[6]](#footnote-6) The participant's consent to continue participating will be documented;
       2. The Researcher must inform former research participants of any new information that may be relevant to their long-term health by contacting them by phone, mail, or in person, if applicable.
4. References

See footnotes and the following references:

* Canadian Association of Research Ethics Boards. History of the Development of the Guidance on Reporting of Unanticipated Problems Including Adverse Events to Research Ethics Boards in Canada July 2010.
* ICH E2A, II.A.1
* Integrated Addendum to E6(R1) ICH Topic E6(R2): Guidance Document: Good Clinical Practice, Health Canada, April 2019, s. 5.17.
* N2 CAREB REB SOPs, published September 29, 2014. [<https://oicronca.app.box.com/s/95k7ydj574579ajvbe06/folder/3403170068>].
* Office for Human Research Protections (OHRP) and Department of Health and Human Services (HHS) – Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events. [http://www.hhs.gov/ohrp/policy/advevntguid.pdf].
* Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada, Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS2-2018).
* USA Food and Drug Administration Code of Federal Regulations Title 21 Part 56.108 (b)
* US Department of Health and Human Services. Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting, January, 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm079753.pdf

1. Revision History

|  |  |  |
| --- | --- | --- |
| **SOP Code** | **Effective Date** | **Summary of Changes** |
| REB-SOP 405A-001 | 2019-04-01 | Original Version |
| REB-SOP 404-002 | YYYY-MM-DD | Updated in line with regulations in effect  Updated references |
|  |  |  |

1. Appendices

1. See REB-SOP 503-002. [↑](#footnote-ref-1)
2. Civil Code of Québec, art. 10 par. 2, 20 and 21. [↑](#footnote-ref-2)
3. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada, Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, 2018, hereafter “TCPS2”, art. 6.16. [↑](#footnote-ref-3)
4. TCPS2, art. 3.3 and 6.15; Guidance Document: Good Clinical Practice: Integrated Addendum to E6(R1) ICH Topic E6(R2), Health Canada, April 2019, s. 4.8.2. [↑](#footnote-ref-4)
5. Be reminded that consent to participate in research may be withdrawn at any time, even verbally. See: Civil Code of Québec, art. 24 par. 3. [↑](#footnote-ref-5)
6. Civil Code of Québec, art. 24 par. 2. [↑](#footnote-ref-6)